[1]胡锦丹,王 宇.丹参酮ⅡA抗癌作用机制研究进展[J].新乡医学院学报,2021,38(11):1079-1083.[doi:10.7683/xxyxyxb.2021.11.016]
点击复制

丹参酮ⅡA抗癌作用机制研究进展
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年11
页码:
1079-1083
栏目:
综述
出版日期:
2021-11-05

文章信息/Info

作者:
胡锦丹1王 宇2
(1.陕西中医药大学基础医学院,陕西 咸阳 712046;2.陕西中医药大学医学科研实验中心,陕西 咸阳 712046)
关键词:
丹参酮ⅡA肿瘤抗肿瘤机制
分类号:
R285.5
DOI:
10.7683/xxyxyxb.2021.11.016
文献标志码:
A
摘要:
丹参是临床常用的一味中药,随着对其药理作用研究的深入,发现其具有良好的抗肿瘤作用。丹参酮ⅡA是丹参的主要成分之一,也是其发挥抗癌活性的重要成分。大量研究证实,丹参酮ⅡA在消化系统肿瘤、妇科肿瘤、肺癌及其他实体肿瘤中可产生显著的抗癌作用,而其发挥作用的主要机制包括:抑制肿瘤细胞增殖、促进肿瘤细胞凋亡、抑制肿瘤细胞的侵袭和迁移能力以及抑制肿瘤细胞的耐药性等。本文就近年来丹参酮ⅡA抗癌作用机制的研究进展进行综述。

参考文献/References:

[1] 代晓光,苏长兰.丹参化学成分及药理研究进展[J].中医药信息,2018,35(4):126-129.
[2] 蔡琳,彭鹏,郭甜.丹参药理作用及临床研究进展[J].山东化工,2016,45(17):51-52.
[3] CHENG T O.Cardiovascular effects of Danshen[J].Int J Cardiol,2007,121(1):9-22.
[4] 刘慧颖,姜长涛,冯娟,等.丹参酮类化合物研究进展[J].中国药理学通报,2016,32(12):1643-1647.
[5] CRONIN K A,LAKE A J,SCOTT S,et al.Annual report to the nation on the status of cancer,part I:national cancer statistics[J].Cancer,2018,124(13):2785-2800.
[6] 孙兰恩,顾萍萍,余亚琼.补中益气汤辅助治疗对结直肠癌术后化疗患者生活质量的影响[J].新中医,2015,47(12):258-260.
[7] MA S,LEI Y,ZHANG L,et al.Research on the inhibiting effect of tanshinone IIA on colon cancer cell growth via COX-2-Wnt/β-catenin signaling pathway[J].J BUON,2018,23(5):1337-1342.
[8] ZHOU L,SUI H,WANG T,et al.Tanshinone IIA reduces secretion of pro-angiogenic factors and inhibits angiogenesis in human colorectal cancer[J].Oncol Rep,2020,43(4):1159-1168.
[9] CAI J,WANG H,JIAO X,et al.The RNA-binding protein HuR confers oxaliplatin resistance of colorectal cancer by upregulating CDC6[J].Mol Cancer Ther,2019,18(7):1243-1254.
[10] LIU Z,YU M,FEI B,et al.Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer[J].Onco Targets Ther,2019,12:2095-2104.
[11] ZHANG Y,GE T,XIANG P,et al.Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via inhibition of ERK/Akt signaling pathway[J].Onco Targets Ther,2019,129725-129734.
[12] HONG H,TAO T,CHEN S,et al.MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase Cepsilon[J].Basic Res Cardiol,2017,112(6):60.
[13] N U 'EZ-G O 'MEZ E,PERICACHO M,OLLAURI-IB N~EZ C,et al.The role of endoglin in post-ischemic revascularization[J].Angiogenesis,2017,20(1):1-24.
[14] QIAN J,FANG D,LU H,et al.Tanshinone IIA promotes IL2-mediated SW480 colorectal cancer cell apoptosis by triggering INF2-related mitochondrial fission and activating the Mst1-Hippo pathway[J].Biomed Pharmacother,2018,108:1658-1669.
[15] ZHANG Y,ZHOU H,WU W,et al.Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways[J].Free Radic Biol Med,2016,95:278-292.
[16] JIEENSINUE S,ZHU H,LI G,et al.Tanshinone IIA reduces SW837 colorectal cancer cell viability via the promotion of mitochondrial fission by activating JNK-Mff signaling pathways[J].BMC Cell Biol,2018,19(1):21.
[17] HE L,GU K.Tanshinone IIA regulates colorectal cancer apoptosis via attenuation of parkin-mediated mitophagy by suppressing AMPK/Skp2 pathways[J].Mol Med Rep,2018,18(2):1692-1703.
[18] GUAN Z,CHEN J,LI X,et al.Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation[J].Biosci Rep,2020,40(8):BSR20201807.
[19] ZHANG Y,GUO S,FANG J,et al.Tanshinone IIA inhibits cell proliferation and tumor growth by downregulating STAT3 in human gastric cancer[J].Exp Ther Med,2018,16(4):2931-2937.
[20] KATSOGIANNOU M,ANDRIEU C,ROCCHI P.Heat shock protein 27 phosphorylation state is associated with cancer progression[J].Front Genet,2014,5:346.
[21] MOON D O,KIM M O,CHOI Y H,et al.Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation[J].Cancer Lett,2010,288(2):204-213.
[22] YIN C F,KAOS C,HSUC L,et al.Phosphoproteome analysis reveals dynamic heat shock protein 27 phosphorylation in tanshinone ⅡA-induced cell death[J].J Proteome Res,2020,19(4):1620-1634.
[23] GORMALLY M V,DEXHEIMER T S,MARSICO G,et al.Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition[J].Nat Commun,2014,5:5165.
[24] YU J,WANG X,LI Y,et al.Tanshinone ⅡA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1[J].Oncol Rep,2017,37(3):1394-1400.
[25] YUAN F,ZHAO Z,JIA B,et al.TSN inhibits cell proliferation,migration,invasion,and EMT through regulating miR-874/HMGB2/β-catenin pathway in gastric cancer.[J].Neoplasma,2020,67(5):1012-1021.
[26] NISHIGUCHI Y,OUE N,FUJIWARA-TANI R,et al.Role of metastasis-related genes in cisplatin chemoresistance in gastric cancer[J].Int J Mol Sci,2019,21(1):254.
[27] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[28] LV C,ZENG H W,WANG J X,et al.The antitumor natural pro-duct tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG[J].Cell Death Dis,2018,9(2):165.
[29] LIN H,ZHENG L,LI S,et al.Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau[J].Phytother Res,2018,32(4):667-671.
[30] LI K,LIU W,ZHAO Q,et al.Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer[J].Phytother Res,2019,33(6):1658-1669.
[31] 张淑娟,周应恩,克尤木·阿不来提.扶正祛瘀汤联合同步放化疗治疗宫颈癌术后患者疗效及对机体免疫功能的影响[J].现代中西医结合杂志,2017,26(26):2921-2923.
[32] 杨惠芬,朱雪琼.腹腔镜下宫颈癌根治术治疗新辅助动脉化疗后巨块型宫颈癌的疗效[J].中国妇幼保健,2017,32(18):4540-4543.
[33] QIN J,SHI H,XU Y,et al.Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity[J].Biomed Pharmacother,2018,105:758-765.
[34] LI N,YANG L,ZHANG B,et al.Tanshinone IIA effects on ovarian cancer cell line[J].J Pharm Pharmacol,2018,70(10):1369-1377.
[35] ZHANG X,ZHOU Y,GU Y.Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways[J].Oncol Lett,2019,17(2):1896-1902.
[36] LEE B Y,TIMPSON P,HORVATH L G,et al.FAK signaling in human cancer as a target for therapeutics[J].Pharmacol Ther,2015,146:132-149.
[37] ZHAO X,GUAN J L.Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis[J].Adv Drug Deliv Rev,2011,63(8):610-615.
[38] HIDA K,MAISHI N,ANNAN D A,et al.Contribution of tumor endothelial cells in cancer progression[J].Int J Mol Sci,2018,19(5):1272.
[39] DE PALMA M,BIZIATO D,PETROVA T V.Microenvironmental regulation of tumour angiogenesis[J].Nat Rev Cancer,2017,17(8):457-474.
[40] RONCA R,BENKHEIL M,MITOLA S,et al.Tumor angiogenesis revisited:regulators and clinical implications[J].Med Res Rev,2017,37(6):1231-1274.
[41] ESWARAPPA S M,FOX P L.Antiangiogenic VEGF-Ax:a new participant in tumor angiogenesis[J].Cancer Res,2015,75(14):2765-2769.
[42] SALVADO M D,ALFRANCA A,HAEGGDSTROM J Z,et al.Prostanoids in tumor angiogenesis:therapeutic intervention beyond COX-2[J].Trends Mol Med,2012,18(4):233-243.
[43] KUJAWSKI M,KORTYLEWSKI M,LEE H,et al.Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice[J].J Clin Invest,2008,118(10):3367-3377.
[44] ZHOU J,JIANG Y Y,WANG X X,et al.Tanshinone IIA suppre-sses ovarian cancer growth through inhibiting malignant properties and angiogenesis[J].Ann Transl Med,2020,8(20):1295.
[45] REINCKE S,GOVBAKH L,WILHELM B,et al.Mutation analysis of the MDM4 gene in German breast cancer patients[J].BMC Cancer,2008,8:52.
[46] PEI D,ZHANG Y,ZHENG J.Regulation of p53:a collaboration between Mdm2 and Mdmx[J].Oncotarget,2012,3(3):228-235.
[47] MOMAND J,VILLEGAS A,BELYI V A.The evolution of MDM2 family genes[J].Gene,2011,486(1/2):23-30.
[48] ZU Y,WANG J,PING W,et al.Tan IIA inhibits H1299 cell viability through the MDM4-IAP3 signaling pathway[J].Mol Med Rep,2018,17(2):2384-2392.
[49] XIE Z,HE B,JIANG Z,et al.Tanshinone IIA inhibits osteosarcoma growth through modulation of AMPK-Nrf2 signaling pathway[J].J Recept Signal Transduct Res,2020,40(6):591-598.
[50] FAN K,FAN Z,CHENG H,et al.Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer[J].Cancer Med,2019,8(13):5903-5915.
[51] ROBEY R B,HAY N.Mitochondrial hexokinases,novel mediators of the antiapoptotic effects of growth factors and Akt[J].Oncogene,2006,25(34):4683-4696.
[52] MAGRI A,REINA S,DE P V.VDAC1 as pharmacological target in cancer and neurodegeneration:focus on its role in apoptosis[J].Front Chem,2018,6:108.
[53] LI M,GAO F,ZHAO Q,et al.Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis[J].Cell Death Dis,2020,11(5):381.
[54] SANTARPIA L,LIPPMAN S M,EL-NAGGAR A K.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy[J].Expert Opin Ther Targets,2012,16(1):103-119.
[55] LIU P,CHENGH,ROBERTS T M,et al.Targeting the phosphoinositide 3-kinase pathway in cancer[J].Nat Rev Drug Discov,2009,8(8):627-644.
[56] SU C.Tanshinone IIA can inhibit MiaPaCa-2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways[J].Oncol Rep,2018,40(5):3102-3111.

相似文献/References:

[1]陈建丽,胡新荣.p16在肿瘤中的表达与人乳头瘤病毒感染的关系[J].新乡医学院学报,,():000.
[2]张明彩 贾红霞 赵卫星 秦志强 付佶.乳腺浸润性导管癌冰冻与石蜡切片细胞核的形态计量对比研究[J].新乡医学院学报,1999,16(02):110.
[3]周文科 综述  张新中 审校.岩斜区侧方手术入路的研究进展[J].新乡医学院学报,2000,17(06):470.
[4]于维霞,王玉红 郭悦鹏,杜荣,等.T细胞亚群测定鉴别结核性与癌性胸腔积液[J].新乡医学院学报,2000,17(01):032.
[5]刘 薇.妇科肿瘤25例动脉插管化疗的观察与护理[J].新乡医学院学报,2003,20(03):003.
[6]刘薇.妇科肿瘤25例动脉插管化疗的观察与护理[J].新乡医学院学报,2003,20(03):001.
[7]王磊,乔庆东,王光军,等.微创腔镜技术治疗输尿管梗阻72 例[J].新乡医学院学报,2010,27(06):610.
[8]郭康,李文才.运动相关蛋白1/CD9在肿瘤中的表达研究进展[J].新乡医学院学报,2010,27(04):419.
[9]张莉莉,黄青松.肿瘤干细胞的起源、分离及鉴定研究进展[J].新乡医学院学报,2012,29(01):000.
[10]职晓松,黄筱奕,訾晓渊,等.长链非编码RNA PVT1在肿瘤中的作用研究进展[J].新乡医学院学报,2016,33(3):243.[doi:10.7683/xxyxyxb.2016.03.022]
 ZHI Xiaosong,HUANG Xiaoyi,ZI Xiaoyuan,et al.Research progress on the role of long-chain noncoding RNAPVT1 in tumors[J].Journal of Xinxiang Medical University,2016,33(11):243.[doi:10.7683/xxyxyxb.2016.03.022]

更新日期/Last Update: 2021-11-05